Ranked #1 in the World
>$40 Million in External Research Income
30 novel drug candidates
2000 undergraduate students
350 publications per year
An Australian register set up to help pregnant women with epilepsy has helped dramatically reduce the number of stillbirths and birth defects such as spina bifida, and the resulting costs to the community, a new Monash University reveals.
An Australian drug delivery technology, developed by Monash University researchers in partnership with PureTech Health plc, has today released results from a multipart Phase 1 trial of the prodrug ‘LYT-300’, an oral form of
The Regional Centre has been established as part of Moderna’s strategic partnership with the Australian Government, and aims to support Australia's mRNA research, development, and industry ecosystem.
The Monash Institute of Pharmaceutical Sciences has been awarded $5.5 million in NHMRC grants to push forward four new exciting research projects.
Professor Ben Boyd has been named the winner of the Australian Synchrotron Lifetime Contribution Award for 2022.
The study, a collaboration between Monash University and the Baker Heart and Diabetes Institute, analysed the cardiovascular and kidney health benefits of SGLT2is - taking into account the economic costs for government.
The number of people who were dispensed opioid painkillers dropped during the height of Victoria’s COVID-19 restrictions, then increased as lockdowns lifted, Monash University researchers have found.
Researchers from the Monash Institute of Pharmaceutical Sciences will lead three projects that will receive a total of $1.84 million through the Australian Research Council’s Discovery Program.
Professor Nicolas Voelcker led the successful application for $984,000 through the ARC’s LEIF funding scheme, with the application a collaborative effort with various Monash faculties, the University of Melbourne, La Trobe University, CSIRO